Develop bifunctional antibody therapies for solid tumors. Focus on ficerafusp alfa, a lead program targeting EGFR and TGF-b. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
There is $414.8M in the vault; even if every debt were paid off, $413.1M would remain.
A loss of $138.0M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 14/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 43/100.
On our five-subject report card, BCAX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BCAX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.